HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Estee Lauder board changes

This article was originally published in The Rose Sheet

Executive Summary

Ronald S. Lauder will retire from The Estee Lauder Companies board of directors, the beauty firm announces July 14. Ronald Lauder has served on the board since 1968. He will continue to serve as chairman of Clinique Laboratories and as an officer of The Estee Lauder Companies. Ronald Lauder's daughter, Jane Lauder, will fill the vacancy on the board. Previously senior VP-global marketing for Clinique, she was named senior VP/general manager of Origins last year 1("The Rose Sheet" June 9, 2008). "Jane's innovative marketing sense, longstanding commitment to our company and proven talent has earned her the respect of our directors. She has a deep understanding of our business and the family values upon which our company has been built," says William P. Lauder, executive chairman of The Estee Lauder Companies

You may also be interested in...



People In Brief

Jane Lauder to manage Origins, Ojon: The Estee Lauder Companies announced that Jane Lauder has been promoted to global president, general manager of Origins and Ojon, effective July 1. She will be responsible for strategic direction, global development, management and growth of both brands and will continue to report to Lynne Greene, global president. "Jane's dynamic leadership skills, marketing creativity and financial acumen have been critical in growing the Origins brand and are important contributors to the company's success. She has led strategic innovation to redefine the brand's positioning in the natural and sustainable beauty brand landscape," says Greene. Lauder was "instrumental" in reasserting Origins as "Powered by Nature, Proven by Science," as well as in brand's launch in China and the introduction of GinZing eye cream, Starting Over moisturizer and Brighter by Nature skin tone correcting serum, firm says. Previously senior VP/general manager of Origins, Jane Lauder replaced father Ronald S. Lauder on the firm's board of directors last summer (1"The Rose Sheet" July 20, 2009, In Brief). Pierce named Aramis VP: Lauder appoints Kathleen Pierce vice president of global communications for its Aramis and Designer Fragrances division, which includes Aramis and Lab Series brands and licenses Tommy Hilfiger, Donna Karan, Michael Kors, Sean John and Coach fragrances. Pierce was previously communications consultant for the division and VP of global communications for BeautyBank, which houses brands American Beauty and Flirt!

People In Brief

New Origins prez: Jane Lauder, Clinique's senior VP-global marketing since July 2006, will begin July 1 as VP, general manager of Estee Lauder's natural-based Origins unit. A former VP at BeautyBank responsible for creation and launch of American Beauty and Flirt! brands, Jane Lauder was "instrumental" in such Clinique successes as Acne Solutions and Almost Powder Makeup - which were driven by innovative multi-media marketing and distribution, parent company notes - as well as Clinique's February debut on QVC, which broke the channel's previous sales records. Her "strong management skills, coupled with her deep understanding of the dynamic global retail environment, will be hugely valuable as she leads and grows the Origins brand around the world," Estee Lauder notes. Jane Lauder -granddaughter of company's founder - will help develop a line of products in collaboration with Allergan that will be distributed through doctors' offices starting later this year. She will report to Jane Hertzmark Hudis, president of BeautyBank, Ojon and now Origins...

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

UsernamePublicRestriction

Register

RS016289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel